Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by topic
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by topic
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are here
Home
Archive
Volume 8, Issue 2
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Responses
Article
metrics
Alerts
PDF
PDF +
Supplementary
Material
Clinical/translational cancer immunotherapy
Original research
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Online download statistics by month:
Online download statistics by month: October 2020 to December 2020
Abstract
Full
Pdf
Oct 2020
261
261
76
Nov 2020
181
180
52
Dec 2020
87
87
33
Total
529
528
161
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
PDF